Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753739 · ClinicalTrials.gov registry record · Phase 2
Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 617
- Enrollment target
NCT01753739 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 617 participants.
The verdict
NCT01753739, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 617 participants
- Enrollment target
Study Summary
This study will examine dose ranging characteristics of bepotastine besilate nasal spray compared to placebo nasal spray in 600 male or female subjects 12 years of age and older with active seasonal allergic rhinitis (SAR) and a demonstrated history of allergic sensitivity to Mountain Cedar pollen for at least 2 years prior to the study.
Interventions
- DRUG Placebo
- DRUG Bepotastine besilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01753739
The ClinicalTrials.gov registry entry for NCT01753739 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 617 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01753739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01753739 about?
NCT01753739 is a clinical study titled "Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)". This study will examine dose ranging characteristics of bepotastine besilate nasal spray compared to placebo nasal spray in 600 male or female subjects 12 years of age and older with active seasonal allergic rhinitis (SAR) and a demonstrated history of allergic sensitivity to Mountain Cedar pollen f...
What is the current status of trial NCT01753739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 617 participants. The study started on 2013-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01753739?
The interventions under investigation include: Placebo (DRUG), Bepotastine besilate (DRUG).
Who is sponsoring clinical trial NCT01753739?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.